141 related articles for article (PubMed ID: 23906078)
1. Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Palombi M; Niscola P; Tendas A; Trawinska MM; Scaramucci L; Giovannini M; Fratoni S; Perrotti A; de Fabritiis P
J Chemother; 2013 Aug; 25(4):247-9. PubMed ID: 23906078
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
3. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
[TBL] [Abstract][Full Text] [Related]
6. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
7. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance.
Horn J; Kleber M; Hieke S; Schmitt-Gräff A; Wäsch R; Engelhardt M
Ann Hematol; 2012 Oct; 91(10):1579-86. PubMed ID: 22752146
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
9. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Weide R; Mergenthaler U; Friesenhahn V; Kleboth K; Heymanns J; Thomalla J; Köppler H
Leuk Lymphoma; 2009 Sep; 50(9):1468-74. PubMed ID: 21049589
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
Merchionne F; Quintana G; Gaudio F; Minoia C; Specchia G; Guarini A; Quarta G; Pavone V; Melpignano A
Leuk Res; 2014 Dec; 38(12):1446-50. PubMed ID: 25455656
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Cheson BD; Crawford J
Br J Haematol; 2015 May; 169(4):528-33. PubMed ID: 25752751
[TBL] [Abstract][Full Text] [Related]
13. Making advances in first-line chronic lymphocytic leukemia treatment.
Wierda WG
J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
[No Abstract] [Full Text] [Related]
14. Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Parker SM; Hyder MA; Fesler MJ
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e15-7. PubMed ID: 24060287
[No Abstract] [Full Text] [Related]
15. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
16. Rituximab plus bendamustine for the treatment of aggressive non-hodgkin lymphoma patients with severe liver impairment.
Ogura M
Clin Adv Hematol Oncol; 2013 Mar; 11(3):188-9. PubMed ID: 23598989
[No Abstract] [Full Text] [Related]
17. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
[No Abstract] [Full Text] [Related]
18. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Friedberg JW
Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
[No Abstract] [Full Text] [Related]
20. Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.
McCloskey JK; Broome CM; Cheson BD
Clin Adv Hematol Oncol; 2013 Mar; 11(3):184-8. PubMed ID: 23598988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
